3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 3
1
Status
Completed
21
Unknown
8
Terminated
6
Withdrawn
2
Recruiting
2
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Gynecologic
1
Gastrointestinal
1
CNS
1
Conditions
Prostatic Neoplasms
5
Polycystic Ovary Syndrome
4
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Insulin Resistance
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Sarcoma, Myeloid
1
Racism
1
Ovarian Neoplasms
1
Neoplasms
1
Melanoma
1
Leukemia, Myeloid, Acute
1
Infertility
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Colorectum
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Brain Neoplasms
1
Anovulation
1
Interventions
Paclitaxel
28
Trastuzumab
22
Cyclophosphamide
21
Doxorubicin
14
Docetaxel
14
Carboplatin
11
exemestane
10
Radiotherapy
10
Letrozole
10
Capecitabine
10
pembrolizumab
8
Lapatinib
8
Fulvestrant
8
Neoadjuvant Therapy
6
Goserelin
6
Bevacizumab
6
Anastrozole
6
pertuzumab
5
palbociclib
5
eribulin
5
abemaciclib
5
Therapeutics
5
Magnetic Resonance Spectroscopy
5
Epirubicin
5
Chemotherapy, Adjuvant
5
Aromatase Inhibitors
5
tucatinib
4
Vinorelbine
4
Taxes
4
Tamoxifen
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Withdrawn
×
Breast Neoplasms
×
Metformin
×
Clear all
NCT04741204
2023-07-06
METBC
Woman's
Phase 4
Withdrawn
NCT02201381
2022-07-18
METRICS
Health Clinics Limited
Phase 3
Withdrawn